Conceptio › Archive › ClinicalTrials.gov
ClinicalTrials.gov public full text Public Domain

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

Apexigen America, Inc. · 2017
ClinicalTrials.gov · Datasets · License: Public Domain · 2017
Open Source ↗
cancerimmunotherapymelanomametastatic-melanomanivolumabpd-1
This study is a Phase 1-2 open-label dose escalation study of the immuno-activating monoclonal antibody APX005M administered in combination with nivolumab to adult subjects with non-small cell lung cancer or metastatic melanoma. The Phase 1 portion is intended to establish the maximum tolerated dose and the recommended phase 2 dose of APX005M when administered in combination with nivolumab. The Phase 2 portion of the study will evaluate safety and efficacy of the combination.
Conceptio Open Archive

Analyze & explore related research in Conceptio

Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.

This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗

Related documents

Record · ID 1338589
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive